IgA directed against early antigen of Epstein-Barr virus is no specific marker for the diagnosis of nasopharyngeal carcinoma

✍ Scribed by Gottfried Sigel; Monika Schillinger; Klaus Henninger; Georg Bauer

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 565 KB
• Volume: 43
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1890430305

✦ Synopsis

Abstract

The aim of this study was to evaluate the significance and specificity of IgA directed against Epstein‐Barr virus (EBV)‐specific early antigens (EA) for the unequivocal diagnosis of nasopharyngeal carcinoma (NPC). Therefore, sera from patients with diseases other than NPC, selected on the basis of elevated antibody titres against EBV antigens, were compared to sera from NPC patients with regard to the presence of IgA directed against EBV viral capsid antigen (VCA‐IgA) and IgA directed against EA (EA‐IgA). Four hundred forty‐seven out of 7,508 non‐NPC sera tested showed high titres (>512) of IgG directed against Epstein Barr viral capsid antigen (VCA‐IgG) and positive VCA‐lgA (⩾32). Two hundred twenty‐seven of these sera were compared to 51 VCA‐IgA‐positive sera from NPC patients regarding the titre of EA‐lgA. 60.7% of VCA‐lgA‐positive NPC sera showed positive EA‐lgA, however 33% of VCA‐IgA‐positive non‐NPC patients also exhibited EA‐lgA. This result demonstrates that EA‐lgA is not specific for NPC and does not allow an unequivocal serological diagnosis of NPC in individual cases. It seems therefore to be of questionable use for screening programs in NPC low‐risk areas. The data do not contradict the usefulness of this marker for monitoring of patients treated for NPC and for screening programmes in high‐risk areas. © 1994 Wiley‐Liss, Inc.